1. Rule of Law
1.1. NCVIA enacted in 1986 that establishes a no-fault compensation program designed to reduce the financial liability of vaccine makers due to vaccine injury claims.
2. Analysis/Application
2.1. NCVIA program is trying to strike a balance between paying victims harmed by vaccines and protecting the vaccine industry from the financial burden under the tort liability.
2.2. The vaccines are intended to be precautionary in nature to save lives of the children from the deadly diseases. Given multiple manufactures have withdrawn from the vaccine market due to high liability cost and NCVIA program have to be created to protect the rights of both consumers and manufacturers.
2.3. Certain side effects will always be there in any medicines and consumer will always have choice to select the manufacture. This is no way to say or to undermine the loss of lives or injuries taken by consumers , it is unfortunate in nature but we also need to make sure that innovation persists in the medical industry to save hundreds of other lives that are in need of critical vaccinations.
3. Conclusion
3.1. Supreme court affirmed the lower's court judgement. Ruling was against the Bruesewitz family under the NCVIA act.
3.2. The manufacturers are immunized from the liability if they have complied with all the regulatory requirements.
3.3. The NCVIA act expressly eliminates liability for a vaccine's unavoidable , adverse side effects.
3.4. The Vaccine manufacturers fund from their sales an informal , efficient compensation program for vaccine injuries and in exchange they avoid the costly tort litigation.
4. Facts
4.1. Parties
4.1.1. Wyeth LLC
4.1.2. Bruesewitz Family
4.2. What Happened
4.2.1. Hannah Bruesewitz was six months old when she received a DTP vaccine and she developed a seizure problem as a side effect.
4.2.2. Hannah's parent filed a claim for relief in the US court and the petition was denied.
4.3. Procedural History
4.3.1. Bruesewitz family filed a case with US court of federal claims under NCVIA and the claim was denied
4.3.2. They then filed a suit in a state court against Wyeth , LLC under strict product liability.
4.3.3. The US court of appeals for the third circuit affirmed the district court's judgement and the Bruesewitz then appealed to the Supreme Court.
5. Issue
5.1. Can federal law protect the drug manufacturers from the liability suit due to injuries or side effects caused from the "life saving" vaccines ?
5.2. Can federal law protect drug manufactures (vaccines in general) from the liability suit based on the design issues in the manufacturing ?
6. Impact
6.1. Sebelius (HEALTH AND HUMAN SERVICES) v. Cloer
6.1.1. 1997 , Cloer begin to experience shortly after receiving her third Hepatitis-B vaccine, Cloer began to experience symptoms for multiple sclerosis (MS) diagnosis in 2003 after her 3rd Hepatitis - B vaccine (1997).
6.1.2. She found a link between her MS and the H-1B vaccine that she received . She Filed for a NCVIA claim.
6.1.3. The court concluded that the claim was untimely because NCVIA act has a 36 months limitation period but because her symptoms started right after her H-1B vaccine , the court ruled in Cloer's favor and Supreme court affirmed.
6.2. Multiple case v HHS
6.2.1. There are multiple instances where defendant were paid compensation in light of the NCVIA act. (refer :https://www.mctlawyers.com/vaccine-injury/cases/)
7. Importance
7.1. NCVIA is especially a good for business that are trying to take a leap in pharma industry. As long as they are compliant with regulatory terms and following ethical practices , the court will protect their rights against unfair claims.
8. Influence
8.1. The act has been amended and influenced the current market in a great deal.
8.1.1. More details has been mentioned in the pharmaceutical products including the benefits and the side affects.
8.1.2. Details regarding NCVIA compensation program has been listed in the pharma products now.